With 47.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 30650.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.93 whereas the lowest price it dropped to was $9.34. The 52-week range on XBIO shows that it touched its highest point at $5.27 and its lowest point at $2.20 during that stretch. It currently has a 1-year price target of $40.00. Beta for the stock currently stands at 2.42.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XBIO was up-trending over the past week, with a rise of 234.19%, but this was up by 234.03% over a month. Three-month performance surged to 170.37% while six-month performance rose 320.28%. The stock gained 159.65% in the past year, while it has gained 126.45% so far this year. A look at the trailing 12-month EPS for XBIO yields -2.00 with Next year EPS estimates of -3.32. For the next quarter, that number is -0.49. This implies an EPS growth rate of 20.62% for this year and -62.75% for next year. EPS is expected to grow by 49.05% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 47.32%.
Float and Shares Shorts:
At present, 1.54 million XBIO shares are outstanding with a float of 1.25 million shares on hand for trading. On 2025-09-15, short shares totaled 23478.0, which was 152.0 higher than short shares on 1755216000.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, XBIO reported revenue of $589897.0 and operating income of -$724412.0. The EBITDA in the recently reported quarter was -$724412.0 and diluted EPS was -$0.45.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.57 being high and -$2.57 being low. For XBIO, this leads to a yearly average estimate of -$2.57. The surprise factor in the prior quarter was -$0.72. Based on analyst estimates, the high estimate for the next quarter is -$0.52 and the low estimate is -$0.52. The average estimate for the next quarter is thus -$0.52.
